Exelixis
EXEL
#2109
Rank
S$9.81 B
Marketcap
$34.41
Share price
-1.53%
Change (1 day)
17.04%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) Fails to deliver data

Key failure to deliver metrics for Exelixis:

A Failure to deliver also known as fails-to-deliver or FTD occurs when a buyer or seller is unable to meet his trading obligations. FTDs for US listed companies are reported to the SEC and published twice a month. Therefore there is a certain delay between the reporting and the publishing of the data.

Failures to deliver for Exelixis (EXEL) - 3 months history

Number of shares, 3 months chart

Biweekly Failures to deliver volume for Exelixis (EXEL) - since 2013

Volume in USD (price x number of shares), data since 2013

Exelixis (EXEL) Failure to deliver volume, Year over Year

Year Volume (Price x Shares) Change
2024S$8.96 M38.21%
2023S$6.48 M-41.81%
2022S$11.14 M-31.9%
2021S$16.36 M-20.71%
2020S$20.64 M303.63%
2019S$5.11 M-70.5%
2018S$17.33 M8.82%
2017S$15.92 M-17.35%
2016S$19.27 M-75.68%
2015S$79.23 M19.37%
2014S$66.37 M258.49%
2013S$18.51 M

FTD volume in the last 3 months for similar companies or competitors

Company FTD volume (3months) FTD volume (1 year) Country
S$22.53 MS$43.31 M๐Ÿ‡ฌ๐Ÿ‡ง UK
S$3.41 MS$70.14 M๐Ÿ‡ซ๐Ÿ‡ท France
S$39.92 MS$95.81 M๐Ÿ‡บ๐Ÿ‡ธ USA
S$36.47 MS$0.31 B๐Ÿ‡บ๐Ÿ‡ธ USA
S$87.32 MS$0.26 B๐Ÿ‡บ๐Ÿ‡ธ USA
S$90.55 MS$0.28 B๐Ÿ‡บ๐Ÿ‡ธ USA
S$0.24 BS$0.50 B๐Ÿ‡บ๐Ÿ‡ธ USA
N/AS$0.06 M๐Ÿ‡บ๐Ÿ‡ธ USA
N/AS$0.04 M๐Ÿ‡บ๐Ÿ‡ธ USA